Rx-to-OTC: Unwanted Attention

June 1, 2001
Kevin Gopal
Kevin Gopal

Kevin Gopal is Pharmaceutical Executive's international correspondent, covering pharma and regulatory issues around the word. He is also a political columnist for North West Business Insider, one of the UK's leading regional business magazines. He started his career as a journalist at SiYu, the UK's Chinese community magazine, before joining the PE staff.

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-06-01-2001, Volume 0, Issue 0

Washington, DC-An FDA advisory committee voted overwhelmingly to recommend that Claritin (loratadine), Allegra (fexofenadine), and Zyrtec (cetirizine) be changed from prescription to over-the-counter products. Although the vote is not binding, FDA usually follows such panels’ recommendations.

Related Content:

News